---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024002"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:18:25.360903+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AVROBIO Q1 net loss $25.0M, cash $72.3M; appoints interim CEO; GD3 trial on track

## Summary
- Net loss of $25.0M for Q1 2023 vs $29.8M in Q1 2022; R&D expenses $17.3M, G&A $7.9M.
- Cash and equivalents $72.3M as of March 31, 2023; expected runway into Q1 2024.
- Plan to initiate registrational Phase 2/3 trial for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.
- Appointed CFO Erik Ostrowski as interim CEO, succeeding Geoff MacKay; board searching for permanent CEO.
- Collaborator-sponsored Phase 1/2 trial for Hunter syndrome (MPS-II) initiated.

## SEC filing metadata
- accession: 0001140361-23-024002
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/0001140361-23-024002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/brhc20052752_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024002
- JSON: https://secwatch.observer/filing/0001140361-23-024002.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024002.txt

## Key facts
- Earnings Releases
  Tectonic Therapeutic, Inc. reported the first quarter ended March 31, 2023 results: net income ($25.0 million).
  - Period: the first quarter ended March 31, 2023
  - Net income: ($25.0 million)
  - Result: reported results
  source text: AVROBIO reported a net loss of $25.0 million for the first quarter of 2023 as compared to a net loss of $29.8 million for the comparable period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/0001140361-23-024002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.